India, July 27 -- British drug major AstraZeneca PLC reported Monday lower pre-tax pofit in its second quarter mainly on lower tax expenses, while earnings per share grew from last year with higher revenues, excluding weak China results. Further, the firm confirmed fiscal 2026 outlook for core earnings and revenue growth.
In the pre-market activity, the shares were gaining around 1.13 percent, trading at $170.96.
On the London Stock Exchange, the shares were at 12,806.00 pence, up 1.07 percent.
Pascal Soriot, Chief Executive Officer, AstraZeneca, said, "While we are disappointed by the CARDIO-TTRansform outcome, we are on track to deliver our $80bn Total Revenue ambition, which assumes successes and setbacks. We remain confident in the s...